Home Cart Sign in  
Chemical Structure| 84573-16-0 Chemical Structure| 84573-16-0

Structure of Rocaglamide
CAS No.: 84573-16-0

Chemical Structure| 84573-16-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Rocaglamide (Roc-A), isolated from the genus Aglaia, is used for treating coughs, injuries, asthma, and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells and a selective inhibitor of heat shock factor 1 (HSF1) activation with an IC50 of ~50 nM. It also inhibits the function of the translation initiation factor eIF4A and has anticancer properties in leukemia.

Synonyms: Roc-A; NSC 326408; Rocaglamide A

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Rocaglamide

CAS No. :84573-16-0
Formula : C29H31NO7
M.W : 505.56
SMILES Code : O=C([C@H]([C@H]1C2=CC=CC=C2)[C@@H](O)[C@]3(O)[C@@]1(C4=CC=C(OC)C=C4)OC5=CC(OC)=CC(OC)=C35)N(C)C
Synonyms :
Roc-A; NSC 326408; Rocaglamide A
MDL No. :MFCD08702699

Safety of Rocaglamide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Rocaglamide (Roc-A), sourced from the Aglaia genus, is utilized for various ailments like coughs, injuries, asthma, and inflammatory skin disorders. It is a potent inhibitor of NF-κB activation in T-cells, a significant and selective suppressor of heat shock factor 1 (HSF1) activation with an IC50 value close to 50 nM, restricts the function of the translation initiation factor eIF4A, and exhibits anticancer effects, particularly against leukemia[1].[2].[3].

In Vitro:

Cell Line
Concentration Treated Time Description References
healthy peripheral blood T cells 100 nM 16 hours Roc-AR does not sensitize healthy T cells to CD95L and TRAIL-induced apoptosis PMC3131883
HeLa cells 50 nM 24 hours FL3 treatment potently inhibited PINK1-PRKN-mediated mitophagy, blocking the recruitment and accumulation of PRKN and PINK1 on mitochondria PMC6999623
HCT116 cells 50 nM 24 hours FL3 or Roc-A treatment markedly increased the protein level of PARL but had no effect on the protein levels of PHB and PHB2 PMC6999623
H460 cells 0, 31.25, 62.5, 125, 250 and 500 nM 24 hours To evaluate the effect of RocA on NK cell-mediated lysis of H460 cells, results showed that RocA enhanced NK cell-mediated lysis of H460 cells. PMC6135631
H1975 cells 250 nM 24 hours To evaluate the effect of RocA on NK cell-mediated lysis of H1975 cells, results showed that RocA enhanced NK cell-mediated lysis of H1975 cells. PMC6135631
A549 cells 250 nM 24 hours To evaluate the effect of RocA on NK cell-mediated lysis of A549 cells, results showed that RocA enhanced NK cell-mediated lysis of A549 cells. PMC6135631
A549 cells 12.5 nM and 25 nM 24 hours RocA significantly increased the expression of CCL5 in A549 cells PMC8741839
H1299 cells 12.5 nM and 25 nM 24 hours RocA significantly increased the expression of CCL5 in H1299 cells PMC8741839
H1975 cells 12.5 nM and 25 nM 24 hours RocA significantly increased the expression of CCL5 in H1975 cells PMC8741839
LLC cells 25 nM and 50 nM 24 hours RocA significantly increased the expression of CXCL10 in LLC cells PMC8741839
U87MG 6.25 nM 24 hours To investigate the effects of Rocaglamide on the translation machinery and protein output in U87MG cells, it was found that it induced the expression of specific proteins and activated the JNK signaling pathway. PMC8558842
Human peripheral blood T lymphocytes 75 nM 24 hours Roc-A significantly reduced apoptosis in T cells induced by DNA-damaging anticancer drugs, with a dose-dependent protective effect. PMC4040689
Human peripheral blood B cells 75 nM 24 hours Roc-A significantly reduced apoptosis in B cells induced by Etoposide. PMC4040689
Human peripheral blood NK cells 75 nM 24 hours Roc-A significantly reduced apoptosis in NK cells induced by Etoposide. PMC4040689
Human neutrophils 75 nM 24 hours Roc-A significantly reduced apoptosis in neutrophils induced by Etoposide. PMC4040689
Human cardiomyocytes 75 nM 24 hours Roc-A significantly reduced apoptosis in cardiomyocytes induced by Etoposide. PMC4040689
Murine hematopoietic stem and progenitor cells 75 nM 24 hours Roc-A significantly reduced apoptosis in murine hematopoietic stem and progenitor cells induced by Etoposide. PMC4040689
HEK 293 cells 30 nM 30 minutes RocA treatment caused a dose-dependent decrease in polysome formation and protein synthesis, inhibiting translation without causing 4EBP dephosphorylation or eIF2α phosphorylation, but partially rescued by expression of RocA-resistant eIF4A proteins. PMC4946961
HEK293 cells 0.3 µM, 3 µM 30 minutes To investigate the perturbation of translation elongation dynamics by RocA, it was found that RocA selectively perturbed the early translation elongation of a set of genes, leading to ribosome collision and reduction of protein synthesis. PMC9891901
HEK293 cells 0.3 μM 30 minutes To evaluate the effect of RocA on translation in HEK293 cells using ribosome profiling, results showed that RocA significantly inhibited the translation of specific mRNAs. PMC6386617
HTLV-1-associated ATL cell lines (SP, MT-2, CHAMP, ATL-3) 100 nM 4 hours Roc-AR inhibits c-FLIP expression and enhances TRAIL and CD95L-induced apoptosis PMC3131883
SP cells 100 nM 4 hours Roc-AR inhibits c-FLIP expression and enhances TRAIL- and CD95L-induced apoptosis PMC3131883
CHAMP cells 100 nM 4 hours Roc-AR inhibits c-FLIP expression and enhances TRAIL- and CD95L-induced apoptosis PMC3131883
M9-ENL cell line 40nM 48 hours Rocaglamide was significantly more cytotoxic to leukemia cells compared to other translation inhibitors such as Temsirolimus. PMC4148474
HEK293 cells 0-10 nM 72 hours To assess the effect of RocA on the viability of HEK293 cells, results showed that RocA significantly inhibited cell viability at low concentrations. PMC6386617

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SCID/Bg mice H1975 cell subcutaneous xenograft tumor model Intraperitoneal injection 0.3 mg/kg Every 2 days, until day 21 To evaluate the inhibitory effect of RocA on H1975 cell subcutaneous xenograft tumors, results showed that RocA significantly inhibited tumor growth. PMC6135631
Mice Foxp3DTR mice Intraperitoneal injection 0.2 mg/kg Once daily for 8 days To test whether RocA could alleviate inflammation caused by Treg depletion, results showed that RocA significantly reduced weight loss and decreased the number of splenic CD4 T cells producing IL-17A or IFNγ. PMC9827529
C57BL/6 mice LLC cell subcutaneous xenograft model intraperitoneal injection 1.0 mg/kg every 2 days for 18 days RocA significantly increased the infiltration of NK cells in tumors and inhibited tumor growth PMC8741839
Mice Patient-derived xenograft model Intraperitoneal injection 1 mg/kg Once daily for 3 days To investigate the effects of Rocaglamide on tumors in vivo, it was found that it induced GEF-H1 protein expression and JNK phosphorylation, leading to tumor cell death. PMC8558842

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.98mL

0.40mL

0.20mL

9.89mL

1.98mL

0.99mL

19.78mL

3.96mL

1.98mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories